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Sensing pathogens is an essential first step in the initiation of a host response to infection. In this issue of
Immunity, Kane et al. (2011) used mouse models to demonstrate that Toll-like receptor 7 is required for
the generation of an antibody response to infection by retroviruses.There are two main classes of sensors
that detect the presence of nucleic acid
components of invading pathogens within
cells (McCartney and Colonna, 2009): the
cytosolic retinoic acid-inducible gene I
(RIG-I)-like receptors (RLRs), which
include LGP2, MDA5, and RIG-I, all of
which are activated by RNA, and the en-
dosomal Toll-like receptors (TLRs). Of
the endosomal TLRs (TLR3, TLR7, TLR8,
and TLR9), TLR3 senses dsRNA, TLR7
and TLR8 recognize ssRNA, and TLR9 is
activated by unmethylated CpG-contain-
ing DNA, which can be found in both
bacterial and certain viral pathogens.
Activation of either cytoplasmic or endo-
somal sensors results in the production
of type 1 interferon (IFN) and inflammatory
cytokines, with dendritic cells (DCs) being
key orchestrators of this innate response
(Gilliet et al., 2008). These cytokines in
turn induce the expression of an array of
genes, the products of which may have
either direct antiviral effects or promote
adaptive immune responses.
As Kane et al. (2011) rightly point out in
this issue of Immunity, the ability of the
various sensors to detect the presence
of certain nucleic acids in vitro is not
necessarily predictive of relevance in the
context of infection in vivo, and so theyemployed mouse models to determine
what might be relevant in vivo sensors of
infection by retroviruses. Mouse strains
vary in their ability to control retroviral
infections through innate and adaptive
immune responses. Thus, beginning with
the reasonable premise that mouse
strains that effectively control retroviral
infections are more likely to be competent
for both sensing and responding to these
pathogens, Kane et al. examined the viral
and host requirements for mobilization of
an antiviral adaptive immune response,
asmeasured by the production of antiviral
antibodies and control of viral replication,
in such strains.
The particular mouse strains used by
Kane et al. included I/LnJ mice, which
are able to control the replication of two
unrelated retroviruses, namely the gam-
maretrovirus murine leukemia virus
(MuLV) and the betaretrovirus mouse
mammary tumor tirus (MMTV). Another
mouse strain, C57BL/6J (B6), is able to
control the replication of MuLV. Both
humoral and cellular immune responses
probably contribute to control of retroviral
infection, but in this study, Kane et al.
focused on the humoral response. Impor-
tantly, by comparing mouse strains that
do, or do not, effectively control MuLVand/or MMTV replication, they show that
the ability to control viral replication corre-
lates well with the ability of a given mouse
strain to mount a robust humoral immune
response to each virus.
To understand what component of the
virus and what aspects of viral replication
might be crucial for viral sensing and
immune control, Kane et al. compared
humoral immune responses to replicating
and inactivated viruses. Whereas MMTV
replication enabled sensing of the virus,
and a humoral immune response in
I/LnJ hosts, heat-inactivated (and thus
replication-defective) MMTV was able to
elicit MMTV antibodies mice only in the
presence of complete Freund’s adjuvant
(CFA), suggesting that CFA is able to
complement for signals generated by viral
replication. Presumably, such signals are
missing, or ineffective, when heat-inacti-
vated virus preparations alone are used
as immunogens.
Importantly, however, UV-inactivated
viruses (which are physically intact, could
enter cells, and were detected in endo-
somes, but could not replicate in vivo)
were capable of eliciting antiviral anti-
bodies when injected into I/LnJ mice.
Kane et al. were able to rule out a require-
ment for the endosomal dsRNA sensor
Figure 1. The Generation of a Humoral Anti-retroviral Adaptive Immune Response Requires
TLR7
TLR7 in endosomal compartments recognizes retroviral ssRNA. Engagement of TLR7 leads to DC
maturation and production of type I IFN and inflammatory cytokines, including IL-6. Both type I IFN and
IL-6 promote the differentiation of B cells into antibody-secreting plasma cells, although in the case of
MuLV and MMTV infections, it appears that type I IFN is dispensable for the generation of antiviral
antibodies. It is also possible that TLR7 in B cells may also affect the humoral response. For both MuLV
and MMTV, virus-specific antibodies play an important role in reducing the numbers of infected cells as
well as reducing transmission of MMTV through milk.
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TLR3-deficientmicewere able to generate
antiviral antibodies to both MMTV and
MuLV. However, a requirement for other
endosomal TLRs, e.g., TLR7 or TLR9,
was suggested by a requirement for the
adaptor molecule MyD88. Both TLR7 and
TLR9 signal via MyD88, and it has been
previously demonstrated that MyD88 is
required for the generation of MuLV anti-
bodies in B6 mice (Browne and Littman,
2009). Kane et al. demonstrate that this is
also true for MMTV in I/LnJmice, suggest-
ing a general role for a MyD88-dependent
pathway in the development of an anti-
retroviral humoral immune response. By
examining the ability of either TLR9-defi-
cient or TLR7-deficient mice to generate
antiviral antibodies, Kane et al. were able
to make the key finding, namely that
whereas TLR9 is dispensable, TLR7 is
specifically required for the development
of antibodies to both MMTV and MuLV.
Activation of both endosomal TLRs and
cytoplasmic nucleic acid sensors leads to
the production of type I IFNs that bind the
IFN-a and IFN-b receptor (IFNAR), result-ing in theactivationofmanyantiviral genes
and promotion of adaptive immune re-
sponses. Somewhat surprisingly, how-
ever, Kane et al. show that antiviral anti-
body production in MuLV-infected B6
mice did not appear to be affected in
IFNAR1-deficient mice, which lack all
type I IFN-dependent signaling. Presum-
ably some other cytokine or pathway
whose expression is activated by TLR7
is more important in eliciting a humoral
immune response, or there is sufficient
redundancy in the system to elicit a
humoral response in the absence of type
1 IFN signaling.
TLR7 has previously been shown to be
involved in detecting a variety of viruses.
Indeed, in vitro studies have suggested
that HIV-1 RNA is recognized by TLR7
(Beignon et al., 2005). TLR7 is primarily
expressed by DCs, and its engagement
by ssRNA leads to the production of type
I IFN as well as inflammatory cytokines
(Figure 1). TLR7 is also expressed at lower
levels in other antigen-presenting cells,
including B cells, and it is also possible
that its presence therein could affect theImmuhumoral response to infection. In contrast
to cytosolic nucleic acid sensors, which
are ubiquitously expressed and activated
in infected cells, endosomal TLRs such
as TLR7 are capable of detecting endocy-
tosed virus in the absence of infection.
Detection leads to cytokine production
as well as DC maturation and subsequent
enhancement of adaptive immune re-
sponses (Stetson and Medzhitov, 2006)
(Figure 1). Thus, targeted stimulation of
TLR7 might be usefully employed in the
context of viral vaccines. Given that the
production of type 1 interferon enhances
B cell function (Theofilopoulos et al.,
2005), it is quite surprising that Kane
et al.were able to show that the generation
of anti-retroviral antibodies was unaf-
fected by the loss of type I IFN signaling.
In future studies, it will be interesting to
assess the contribution of other cytokines
(e.g., IL-6) elicited by TLR7 engagement
in the promotion of anti-retroviral humoral
immune responses; again this might
inform vaccine development.
Although Kane et al. clearly identify
TLR7 as a key immune sensor of retroviral
infection, they stop short of implicating
TLR7 as the defining difference between
mouse strains that vary in their ability to
control retroviral infection. Indeed, both
retrovirus-sensitive and resistant mice
express TLR7. However, given the impor-
tance of TLR7 dosage on immune
responses (Deane et al., 2007), it would
be interesting to know if there are any
differences in TLR7 expression level
betweenmouse strains. It is also possible,
as Kane et al. point out, that the differ-
ences between resistant and susceptible
strains lie downstream of TLR7 or
perhaps with other viral sensors or anti-
viral proteins. The array of molecules
known to influence the course of retroviral
infections in both mice and humans is
ever expanding, and although innate
sensors do affect sensitivity to retroviral
infection, they are unlikely to be the sole
determinants of the course of infection.
The pathways involved in retrovirus
sensing are an area of intense current
research. Retroviruses are somewhat
unusual that the viral genome and replica-
tion intermediates are either present at
low abundance in individual cells (as pre-
integrated DNA) or essentially indistin-
guishable in form from cellular nucleic
acids (as integrated proviral DNA, or viral
mRNA and genomes). Retroviral nucleicnity 35, July 22, 2011 ª2011 Elsevier Inc. 9
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Previewsacids may also be concealed from the
host sensors at certain phases of the viral
life cycle by the incoming viral capsid
structure or by association with the prein-
tegration complex. Cyclophilin A, a mole-
cule long known to be involved in retro-
viral replication, has recently been
suggested to be involved in sensing retro-
viral infections (Manel et al., 2010), as has
TRIM5, a molecule that also has direct
antiretroviral activity (Pertel et al., 2011).
The findings of Kane et al. are an impor-
tant addition to our growing under-
standing of how cells detect the presence
of these lethal pathogens.10 Immunity 35, July 22, 2011 ª2011 ElsevieREFERENCES
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Deliberate redirection of T cell responses to human immunodeficiency virus-1 might enhance immunity and
thus aid viral containment. Dahirel et al. (2011) identify candidate antigens to achieve this with a theory
derived from physics.The elephant in the conference room for
those working with human immunodefi-
ciency virus (HIV) vaccines is that despite
30 years of intense scientific effort and
extremely generous global funding, we
have no tenable vaccine. This research
effort and the money spent have told us
much about the virus and the immunity it
evokes, but there has been no translation
to a preventative vaccine. So far three
large trials have failed to demonstrate
protection against HIV-1 infection.
We still do not knowwhat form of immu-
nity a vaccine must engender to prevent
infection. The STEP trial has severely
tempered enthusiasm for T cell vaccines
(Buchbinder et al., 2008), but despite the
negative result, the boosting or enhance-
ment of anti-HIV cytotoxic T cells (CTLs)
remains a stoical ambition ofmany groups.
The enduring inspiration for this aim is the
fact that HIV-1-specific CTLs do seem
responsible for containment of the infec-tion. Uncommonly, some individuals sup-
press HIV replication so well that virus is
not detectable in their plasma. This
phenomenon has been attributed, in part,
to HIV-1-specific CTLs. Many of these
patients have particular human leucocyte
antigen (HLA) class I molecules that confer
benefit in ways we barely understand. If
CTL responsescouldbeartificially boosted
or redirected to the ‘‘right’’ antigens, then
could protective immunity be induced or
chronically infected patients be converted
into ‘‘elite controllers’’?
Natural and artificially induced CTLs
select retroviral mutants that evade im-
mune recognition (Phillips et al., 1991); the
impact on clinical progression that immune
escape confers is not clear. In an apparent
paradox, immune escape might even slow
progression, depending on the precise
mutations that confer this effect (Frater
et al., 2007). Methods that quantify viral
replicative capacity, or ‘‘fitness,’’ ex vivohave shown that immune escape muta-
tions in certainHIVepitopesare associated
with fitness costs whereas others exact no
price. Three findings in patients strongly
support the notion that some immune
escape mutants impair virus replication:
(1) the reversion of mutations upon trans-
mission to new hosts who do not carry
the same HLA class I alleles (Leslie et al.,
2004), (2) preliminary observations that
immune escape may revert in end-stage
AIDS as the immune system weakens
(Huang et al., 2011), and (3) the identifica-
tion of compensatory viral mutations that
partially or fully reinstate viral fitness (Craw-
ford et al., 2007). There is a dynamic
between the triad of CTL pressure, viral
adaptation, and viral fitness. The outcome
of this battle will influence, perhaps mark-
edly, clinical progression (Figure 1).
In the 108th edition of the Proceedings
of the National Academy of Science, Da-
hirel et al. (2011) report the application of
